Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
Chimeric Newcastle disease viruses and uses thereof
US9217136B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9217136-B2 |
| Application number | US-201314060166-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 22, 2013 |
| Priority date | Feb 5, 2009 |
| Publication date | Dec 22, 2015 |
| Grant date | Dec 22, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.
First claim
Opening claim text (preview).
What is claimed: 1. A chimeric Newcastle disease virus (NIV), comprising a packaged genome which encodes a heterologous interferon antagonist and a modified F protein with a mutated cleavage site, wherein the heterologous interferon antagonist and the modified F protein are expressed by the virus. 2. The chimeric NDV of claim 1 , wherein the heterologous interferon antagonist is an influenza virus NS1 protein. 3. The chimeric NDV of claim…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9217136B2 cover?
- Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.
- Who is the assignee on this patent?
- Sinai School Medicine, Sloan Kettering Inst Cancer, Icahn School Med Mount Sinai
- What technology area does this patent fall under?
- Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).